1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Astex Pharmaceuticals, Inc. - Strategy and SWOT Report

Astex Pharmaceuticals, Inc. - Strategy and SWOT Report

  • February 2016
  • -
  • MarketLine
  • -
  • 21 pages

Summary

Table of Contents

Search Inside

Introduction

Astex Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Astex Pharmaceuticals, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Astex Pharmaceuticals, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Astex Pharmaceuticals, Inc. including a breakdown and examination of key business segments

- Intelligence on Astex Pharmaceuticals, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Astex Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Astex Pharmaceuticals, Inc. (Astex or 'the company'), a subsidiary of Otsuka America, Inc., is engaged in the discovery, development and commercialization of cancer therapies in the US. The company is headquartered in Dublin, California. In 2013, Otsuka Pharmaceutical, a wholly-owned subsidiary of Otsuka Holdings, completed the acquisition of Astex. Astex has not disclosed its financial details including revenue, and operating and net profits.

Reasons to Purchase:

- Gain understanding of Astex Pharmaceuticals, Inc. and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Astex Pharmaceuticals, Inc. as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Astex Pharmaceuticals, Inc.’s business structure, strategy and prospects

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.